Challenges in optimizing EU market access for immuno-oncology therapies

With CAR-T therapies closer than ever to delivering on their promise but still facing significant obstacles, Eva Marchese (pictured above) and Cécile Matthews from Charles River Associates provide an Expert View on the topic.

Since the approval of Yervoy (ipilimumab) in 2011 for the treatment of melanoma, the idea of mobilizing a patient’s immune system to combat a wide range of cancers has been transformed from a promising concept to an emerging standard for oncology therapies.

Today, there are several approved immuno-oncology (I-O) products on the market and many more in clinical development – including monoclonal antibody treatments that target specific immune checkpoint receptors such as programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand (PD-L1).